View Clinical Trial (Medical Research Study)

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression - NCT00812058-77030(Clinical Trial 472435)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Houston
State:  
TX
Zip Code: 77030
Conditions: Bipolar I Depression
Purpose: The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
Study summary:
Criteria: Inclusion Criteria: - Bipolar I Disorder, most recent episode depressed - History of 2 or more manic or mixed episodes, at least one of which required pharmacologic treatment for manic symptoms Exclusion Criteria: - Current manic, hypomanic or mixed episode - Rapid cycling bipolar disorder (4 or more mood episodes in the last year) - Dementia or any other Axis I diagnosis (besides bipolar I) that requires treatment - Alcohol or drug dependence within 6 months; alcohol or drug abuse within 3 months - Positive urine drug test for amphetamines, cocaine metabolites, opiates and/or phencyclidine(PCP) - Axis II diagnosis likely to interfere with study compliance - Serious suicidal or homicidal risk - Sensitivity to any of the drug ingredients, including lactose - Women who are pregnant, breast feeding or refuse to use adequate birth control - Current seizure disorder - Current episode of depression is longer than 1 year
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: October 7, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.